NR-56461SARS相关冠状病毒2,分离株hCoV-19/USA/MD-HP20874/2021(谱系B.1.1.529;Omicron变体)(病毒)
产品图片
货号/SKU
NR-56461
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、3
产品描述信息
NR-56461??SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP20874/2021 (Lineage B.1.1.529; Omicron Variant) (Viruses)|SARS-Related Coronavirus 2|Isolate hCoV-19/USA/MD-HP20874/2021 (Lineage B.1.1.529; Omicron Variant) |-60°C or colder|AS PekoszAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP20874/2021 (Lineage B.1.1.529; Omicron Variant), NR-56461, contributed by Andrew S. Pekosz."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Due to the high volume of orders, NIAID will prioritize shipments.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD-HP20874/2021 was isolated from a nasal swab in Maryland, USA, on November 27, 2021.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/MD-HP20874/2021 is assigned lineage B.1.1.529 (Pango v.3.1.17 2021-12-06) and GISIAD clade GRA using Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) tool. The complete genome of the clinical isolate of SARS-CoV-2, hCoV-19/USA/MD-HP20874/2021 has been sequenced (GISAID: EPI_ISL_7160424). The following mutations are present: Spike A67V, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G446S, Spike G496S, Spike H69del, Spike H655Y, Spike ins214EPE, Spike K417N, Spike L212I, Spike L981F, Spike N211del, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N856K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike S477N, Spike T95I, Spike T478K, Spike T547K, Spike V70del, Spike V143del, Spike Y144del, Spike Y145del, Spike Y505H, E (Envelope) T9I, M (Membrane) A63T, M D3G, M Q19E, N (Nucleocapsid) E31del, N G204R, N P13L, N R32del, N R203K, N S33del, NSP3 (Non-structural protein 3) A1892T, NSP3 K38R, NSP3 L1266I, NSP3 S1265del, NSP3 T1004I, NSP4 (Non-structural protein 4) T492I, NSP5 (Non-structural protein 5) P132H, NSP6 (Non-structural protein 6) G107del, NSP6 I189V, NSP6 L105del, NSP6 S106del, NSP12 (Non-structural protein 12) P323L, NSP14 (Non-structural protein 14) I42V. It was labelled as an VOC Omicron GR/484A (B.1.1.529+BA.1), first detected in Botswana/Hong Kong/South Africa by the World Health Organization (WHO).
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3) infected with SARS-CoV-2, isolate hCoV-19/USA/MD-HP20874/2021.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD-HP20874/2021 was isolated from a nasal swab in Maryland, USA, on November 27, 2021.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/MD-HP20874/2021 is assigned lineage B.1.1.529 (Pango v.3.1.17 2021-12-06) and GISIAD clade GRA using Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) tool. The complete genome of the clinical isolate of SARS-CoV-2, hCoV-19/USA/MD-HP20874/2021 has been sequenced (GISAID: EPI_ISL_7160424). The following mutations are present: Spike A67V, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G446S, Spike G496S, Spike H69del, Spike H655Y, Spike ins214EPE, Spike K417N, Spike L212I, Spike L981F, Spike N211del, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N856K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike S477N, Spike T95I, Spike T478K, Spike T547K, Spike V70del, Spike V143del, Spike Y144del, Spike Y145del, Spike Y505H, E (Envelope) T9I, M (Membrane) A63T, M D3G, M Q19E, N (Nucleocapsid) E31del, N G204R, N P13L, N R32del, N R203K, N S33del, NSP3 (Non-structural protein 3) A1892T, NSP3 K38R, NSP3 L1266I, NSP3 S1265del, NSP3 T1004I, NSP4 (Non-structural protein 4) T492I, NSP5 (Non-structural protein 5) P132H, NSP6 (Non-structural protein 6) G107del, NSP6 I189V, NSP6 L105del, NSP6 S106del, NSP12 (Non-structural protein 12) P323L, NSP14 (Non-structural protein 14) I42V. It was labelled as an VOC Omicron GR/484A (B.1.1.529+BA.1), first detected in Botswana/Hong Kong/South Africa by the World Health Organization (WHO).
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3) infected with SARS-CoV-2, isolate hCoV-19/USA/MD-HP20874/2021.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.在此限制上订单将在发货前发送至NIAID进行批准. 由于秩序量大,NIAID将优先考虑出货量.
与美国马里兰州马里兰州的鼻拭子分离出严重急性呼吸综合征相关的冠状病毒2(SARS-COV-2),分离atateHcoV-19 / USA / MD-HP20874 / 2021,于20021年11月27日,美国马里兰州的纳尔棉签中分离出来. >
注意:基因组序列信息在分析证书上提供,并且包括对每个批次观察到的所有序列变化的分析.
根据GISAID引入的命名系统(全球共享所有流感数据的倡议),SARS-COV-2,隔离HCOV-19 / USA / MD-HP20874 / MD-HP20874 / MD-HP20874 / MD-HP20874 / MD-HP20874 / MD-HP20874 / MD-HP20874 / MD-HP20874 / 2021(Pango V.1.17 2021-12-06)和GISIAD CLADE GRA使用名为Global爆发谱系(Pango)工具的系统发育分配. SARS-COV-2的临床分离物的完整基因组(HCOV-19 / USA / MD-HP20874 / 2021)已经排序(GISAID:EPI_ISL_7160424). The following mutations are present: Spike A67V, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G446S, Spike G496S, Spike H69del, Spike H655Y, Spike ins214EPE, Spike K417N, Spike L212I, Spike L981F, Spike N211del, Spike N440K , Spike N501Y, Spike N679K, Spike N764K, Spike N856K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike S477N, Spike T95I, Spike T478K, Spike T547K, Spike V70del, Spike V143del, Spike Y144del, Spike Y145Del,尖峰Y505H,E(封套)T9I,M(膜)A63T,M D3G,M Q19E,N(核衣壳)E31DEL,N G204R,N P131,N R32DEL,N R203K,N S33DEL,NSP3(非结构蛋白3)A1892T,NSP3 K38R,NSP3 L126II,NSP3 S1265DEL,NSP3 T1004I,NSP4(非结构蛋白4)T492I,NSP5(非结构蛋白5)P132H,NSP6(非结构蛋白6)G107DEL,NSP6 I189V,NSP6 L105DEL,NSP6 S106DEL,NSP12(非结构蛋白12)P323L,NSP14(非结构蛋白14)I42V.它被标记为VOC OMICRON GR / 484A(B.1.1.529 + BA.1),由世界卫生组织(世卫组织)在博茨瓦纳/香港/南非检测到检测.
每个小瓶含有大约0.1ml的旋转澄清的细胞裂解物和来自 Homo sapiens的上清液肺腺癌上皮细胞(Calu-3)感染SARS-COV-2,分离HCOV-19 / USA / MD- HP20874 / 2021.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2022-04-01
2023-09-21
2020-08-04
2021-12-13
2020-08-04
2024-05-19
2022-04-01
2021-12-02
2021-12-13
2022-04-01